CN114410608B - Method for efficiently expressing and purifying Cas9 protein and application thereof - Google Patents
Method for efficiently expressing and purifying Cas9 protein and application thereof Download PDFInfo
- Publication number
- CN114410608B CN114410608B CN202210054940.3A CN202210054940A CN114410608B CN 114410608 B CN114410608 B CN 114410608B CN 202210054940 A CN202210054940 A CN 202210054940A CN 114410608 B CN114410608 B CN 114410608B
- Authority
- CN
- China
- Prior art keywords
- spcas9
- protein
- expression
- cas9
- pet28a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a method for efficiently expressing and purifying Cas9 protein and application thereof. The invention mainly comprises construction of a Cas9 expression vector, transformation of escherichia coli, induction expression of Cas9 protein, purification of Cas9 protein and application in vitro and in vivo. The GB1 is used as a dissolution promoting tag, so that the stability and the solubility of the SpCas9 can be increased, the expression quantity of the SpCas9 is primarily improved, the function of the SpCas9 is not affected by the GB1, and the SpCas9 is not required to be removed later, so that the method is simple, convenient and feasible. And by using a 10 XHis tag, the high affinity of the fusion protein and Ni-NTA resin is facilitated, the high salt washing is facilitated, the polluted nucleic acid is removed, and the purification effect is improved. The tandem T7 promoter is used for obviously improving the expression quantity of the SpCas 9. Through in vivo and in vitro application, the purified SpCas9-GB1 protein is proved to be correctly folded, has the capability of cutting DNA and can enter a nucleus for gene editing.
Description
Technical Field
The invention belongs to the technical fields of biotechnology and genetic engineering, relates to a nuclease Cas9-GB1 protein expression vector driven by multiple promoters and a protein expression and purification method, and in particular relates to a method for efficiently expressing and purifying Cas9 protein and application thereof.
Background
The use of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) -related RNA-guided Cas9 endonuclease activity derived from prokaryotes makes gene editing in multiple species simple and rapid. The CRISPR system mainly comprises two parts, namely Cas9 protein and single guide RNA (sgRNA). Cas9 proteins are nucleases containing two domains with cleavage activity: HNH domain and RuvC domain, which can be directed to specific locations to cleave target sites in the presence of gRNA, resulting in DNA double strand breaks. CRISPR systems have been applied to gene editing of multiple species.
Riboprotein complexes (RNPs) formed by in vitro assembly of Cas9 protein and sgrnas also have gene editing capabilities and have also been used in a variety of organisms for gene editing. Gene editing of RNP has several advantages: if RNP avoids translation expression in a host body, is easy to degrade, and can reduce off-target effect by performing instantaneous cleavage on a host genome; different sites can be targeted only by replacing sgRNA, so that the complicated process of constructing plasmids is omitted, and the flux gene editing is convenient; meanwhile, RNP can also be used for in vitro cutting of templates to verify the efficiency of sgRNA.
At present, in the process of expression and purification of Cas9 protein, insoluble protein in the form of inclusion bodies is easy to form, the problems of incorrect protein folding, low yield and the like caused by high endotoxin content and overlarge protein are easy to occur, and in addition, cas9 protein in the current market is expensive, so that the popularity of in-vitro assembly and in-vivo editing of a Cas9 system is limited.
Disclosure of Invention
In order to overcome the disadvantages and shortcomings of the prior art, the present invention is directed to a method for efficiently expressing and purifying Cas9 protein. The method is a Cas9 protein expression purification method capable of performing gene editing and remarkably improving the in vitro cutting expression quantity. The invention mainly comprises construction of a Cas9 expression vector, transformation of escherichia coli, induction expression of Cas9 protein, purification of Cas9 protein and application in vitro and in vivo. In the constructed pet28a+ -SpCas9-GB1-10 xHis-3T 7 vector, GB1 is used as a dissolution promoting tag, so that the stability and the solubility of the SpCas9 can be increased, the expression quantity of the SpCas9 is primarily improved, and the function of the SpCas9 is not influenced by GB1, so that additional removal is not needed in the follow-up process, and the method is simple, convenient and feasible. And by using a 10 XHis tag, the high affinity of the fusion protein and Ni-NTA resin is facilitated, the high salt washing is facilitated, the polluted nucleic acid is removed, and the purification effect is improved. The method of using the tandem T7 promoter obviously improves the expression quantity of the SpCas 9. Through in vivo and in vitro application, the purified SpCas9-GB1 protein is proved to be correctly folded, has the capability of cutting DNA, and can enter a nucleus for gene editing.
The aim of the invention is achieved by the following technical scheme:
a method for efficiently expressing and purifying Cas9 protein, comprising the steps of:
step 1, constructing a nuclease Cas9 expression vector pet28a+ -SpCas9-GB1-10 xHis-3T 7 driven by multiple promoters;
step 2, expression of the cas9 expression vector pep28a+ -SpCas9-GB1-10 xhis-3T 7: transferring the constructed pet28a+ -SpCas9-GB1-3T7 into a host E.coli Rosetta (DE 3) to obtain a recombinant strain; transferring and activating the recombinant strain, performing induction expression by using IPTG, and centrifugally collecting thalli to obtain thalli expressing the SpCas9-GB1 protein;
step 3, purification of SpCas9-GB1 protein: suspending the strain in the step 2 by using a buffer solution, performing ultrasonic crushing, centrifuging and collecting the supernatant to obtain soluble SpCas9-GB1 protein in positive clones, filtering to remove cell fragments and particles, directly loading the filtered liquid to a Ni+ affinity chromatography column for purification, and collecting eluted protein to obtain SpCas9-GB1 protein solution; and carrying out ultrafiltration concentration on the obtained SpCas9-GB1 protein solution to obtain the SpCas9-GB1 protein.
In order to better implement the present invention, the method further includes step 4:
step 4, application of SpCas9-GB1 protein: the SpCas9-GB1 and the sgRNA are assembled and then used for in-vitro cutting of templates and gene editing by transferring into a fungus host, and whether the SpCas9-GB1 is correctly folded or not is determined to have the capability of cutting DNA and performing gene editing by nuclear insertion.
Further, the vector construction in step 1: the 6 Xthioredoxin-histidine tag on the pet28a+ plasmid was replaced with a 10 Xthioredoxin-histidine tag, the number of T7 promoters was increased to 3, while the 56-residue B1 immunoglobulin binding domain of streptococcal protein G (Streptococcal protein G, GB 1) was used as fusion tag to ligate with Cas9 protein through linker (ggtggagcaggtggcagtggcgcagggggagccgga), the entire Cas9-GB1 gene sequence, which was codon optimized for easy expression in E.coli, was ligated with the 10 Xthioredoxin-histidine tag of pet28 a+. The optimization replaces the rare codon in the original GB1 sequence and the base which is not easy to translate protein with the base which is easy to translate and express in host bacteria.
Furthermore, the SpCas9-GB1-10 xHis has a sequence shown in SEQ ID NO:19.
Further, the recombinant strain in the step 2 is selected in LB liquid medium of Kan+ and CHL+, and cultured for 8-16 h activation at 37+ -1 ℃ and 200-220 rpm (preferably, the activation is performed at 37+ -1 ℃ and 220 rpm); after activation, according to (1-5): 100 transferring ratio, taking activated bacterial liquid in LB liquid culture medium of Kan+ and CHL+, culturing at 37+ -1deg.C and 200-220 rpm to OD 600 At 0.6 to 0.8, IPTG is added to a final concentration of 0.3 to 0.8mM (preferably 0.5 mM) to induce expression.
Further, the conditions for inducing expression in the step 2 are 16-20 ℃ and 200-220 rpm; the fermentation time is 18-22 h.
Further, the centrifugation condition in the step 2 is 4-8 ℃, 8000-10000 rpm for 5-10 minutes; further, the mixture was centrifuged at 8000rpm at 4℃for 5 minutes.
Further, the conditions of ultrasonic disruption in step 3 are: the ultrasonic switch is turned on for 3s, the ultrasonic switch is turned off for 3s, the power is 30-40% (preferably 30%), and the ultrasonic switch is used for 20-30 min (preferably 20 min) on ice.
Further, the centrifugation condition in the step 3 is 4-8 ℃, and centrifugation is carried out at 8000-10000 rpm for 30-40 min; further, the mixture was centrifuged at 10000rpm at 4℃for 30min.
Further, in step 3, the SpCas9-GB1 protein was eluted using a gradient elution with Buffer A (500mM NaCl,20mM Tris-HCl, pH=8.0) at an imidazole concentration of 0mM and Buffer B (500mM NaCl,500mM Imidazole,20mM Tris-HCl, pH=8.0) at an imidazole concentration of 500mM. The gradient was 5%, 10%, 20%, 30%, 50% buffer B.
Further, in step 4, all sgrnas were T7 transcribed in vitro. The in vitro cleavage template was the Niad site of A.oryzae and the in vivo gene editing was the pyrg site of A.niger. The Buffer used is a commercial Cas9 protein matched Buffer.
The method for efficiently expressing and purifying the Cas9 protein is applied to efficiently expressing and purifying the Cas9 protein.
Compared with the prior art, the invention has the following advantages and effects:
(1) The invention is thatThe GB1 is used as a dissolution promoting tag and a 10 XHis tag to fusion express the SpCas9, so that the stability of the SpCas9 is improved, the nucleic acid pollution is avoided, and the purification effect is improved. By Ni 2+ The high-purity SpCas9-GB1 protein can be effectively obtained through affinity chromatography column purification, and the obtained SpCas9-GB1 protein is correctly folded. And GB1 does not have influence on the SpCas9 function, does not need to be removed later, and is very convenient.
(2) The invention utilizes a tandem T7 promoter, and under the condition of a triple T7 promoter, the expression quantity of the SpCas9-GB1 protein is further increased.
(3) Through in-vitro and in-vivo application of the purified SpCas9-GB1 protein, the invention verifies that a complex formed by the purified Cas9-GB1 and sgRNA can effectively cut in-vitro DNA fragments and in-vivo targeted genes. The SpCas9-GB1 protein related to the invention is easy to purify, has high purification degree and high cleavage activity, and can be used for industrial production of Cas9 protein and laboratory Cas9 protein sources.
(4) The invention fuses NLS nuclear localization signal peptide at the C end of Cas9 protein. The NLS nuclear localization signal peptide can enable the protein to be used for in vitro cutting and gene editing of prokaryotes, and is also suitable for genome editing of eukaryotes.
Drawings
FIG. 1 is an agarose gel electrophoresis of the results of digestion of the pet28a+ plasmid.
FIG. 2 is a graph of the sequencing results of the pet28a+ multiple promoter vector.
FIG. 3 is a agarose gel electrophoresis chart (A, B) of the PCR results of SpCas9, spCas9-N, spCas9-C, GB1-C, GB1-N and a agarose gel electrophoresis chart (B) of the digestion results of pet28a+ plasmid.
FIG. 4 is an agarose gel electrophoresis of the pet28a+ -2T7 plasmid using both NcoI and XhoI digestion.
FIG. 5 is a map of the pet28a+ -SpCas9-GB1-10 XHis-3T 7 plasmid.
FIG. 6 is a SDS-PAGE analysis of the effect of GB1 on SpCas9 expression; wherein His-SpCas9 refers to SpCas9; NGB1-SpCas9 refers to GB1-SpCas9; spCas9-CGB1 refers to SpCas9-GB1.
FIG. 7 is a graph showing the effect of SDS-PAGE analysis of multiplex promoters on SpCas9 expression; wherein A is the influence of multiple promoters on the expression quantity of NGB1-SpCas9 (namely GB1-SpCas 9); b is the influence of multiple promoters on the expression quantity of the SpCas9-CGB1 (namely, the SpCas9-GB 1).
FIG. 8 is a SDS-PAGE analysis gel of SpCas9-GB1 protein after AKTA pure Ni-NTA column purification.
FIG. 9 is a diagram of agarose electrophoresis gel of sgRNA transcription template PCR.
FIG. 10 is a diagram showing an example of the application of the purified SpCas9-GB1 protein; wherein, cas9-GB1 refers to SpCas9-GB1.
FIG. 11 is a diagram of an example in vivo editing application of the purified SpCas9-GB1 protein; wherein A is a positive control plate and a negative control plate, wherein the positive plate is an RNP complex-free plate and no screening substances (5-fluoroorotic acid and uridine) are added; the negative plate is not added with RNP complex, and screening substances are applied; b is a transformation plate, which is an RNP complex added, and a screening substance is applied.
FIG. 12 is a schematic (A) and a result chart (B) of the purified SpCas9-GB1 protein gene editing.
Detailed Description
The present invention will be described in further detail with reference to examples and drawings, but embodiments of the present invention are not limited thereto.
The test methods for specific experimental conditions are not noted in the examples below, and are generally performed under conventional experimental conditions or under experimental conditions recommended by the manufacturer. The materials, reagents and the like used, unless otherwise specified, are those obtained commercially.
The materials used in the examples are as follows:
1. cell source: e.coli Mach 1T 1, E.coli Rosetta (DE 3), are conventional commercial strains.
2. Plasmid source: the pET-28a (+) plasmid is a conventional commercial product.
3. Primer source primer: are synthesized in the Shanghai stock of biological engineering, guangzhou Tian Yihui Yuan Gene technology Co.
4. The main reagent comprises: all are commercial products.
Example 1 construction of pet28a+ -SpCas9-GB1-10 XHis-3T 7 plasmid
Construction of Pet28a+ multiple promoter vector
According to the pET-28a (+) plasmid, a pair of primers F-1/R-1 (SEQ ID NO: 1-2) are designed, and the pET-28a (+) plasmid is used as a template, and a pET28a+ linearization skeleton fragment is obtained through PCR reaction. The PCR reaction system is shown in Table 1.
TABLE 1 PCR reaction System
Reaction components | Volume of |
2×Primer Star | 25μL |
F-1~F-6(10μM) | 0.5μL |
R-1~R-6(10μM) | 0.5μL |
pET-28a (+) plasmid | 1μL(10ng) |
Ultrapure water | Up to 50μL |
Linear amplification reaction procedure:
reaction temperature | Time |
98℃ | 2min |
98℃ | 30s |
62 ℃ (tm value) | 30s |
72℃ | 1Kb/min |
72℃ | 7min |
25℃ | 1s |
The PCR results are shown in FIG. 1. Lane 1 is pet28a+ PCR backbone fragment, lane 2 is DNA 1Kb marker. Recovering the fragment.
Multiple promoter primers (Table below) were designed and 2T7-F/2T7-R, 3T7-F/3T7-R, 4T7-F/4T7-R (SEQ ID NOS: 3-8) were annealed at 98℃for 10min, respectively, to form multiple promoter 2T7 fragments, 3T7 fragments, 4T7 fragments. Recovering the fragment.
Pet28a+ linearized fragments 0.5. Mu.L, 2T7 fragment, 3T7 fragment or 4T7 fragment 4.5. Mu.L, infusion enzyme 5. Mu.L were added to PCR tubes and ligated at 50℃for 1 h.
Transferring the above connection products into E.coli Mach 1T 1 competent cells by 42 ℃ heat shock method, adding 890 μl of LB liquid medium, placing in a shaking table at 37 ℃ for culturing at 200rpm for 1h, coating 200 μl on Kan+ resistant LB solid plate, and culturing in a 37 ℃ incubator overnight.
Microcolonies on the plates were picked, amplified in small amounts, subjected to bacterial liquid electrophoresis, and observed for correct plasmid size. Randomly picking plasmids with correct band sizes, carrying out sequencing, and obtaining the pet28a+ -2T7, pet28a+ -3T7 and pet28a+ -4T7 plasmids after the correct sequencing is identified. The sequencing results are shown in FIG. 2.
Construction of pet28a+ -6×his-SpCas9, pet28a+ -10×His-GB1-SpCas9, pet28a+ -SpCas9-GB1-10×His plasmids
The pET-28a (+) plasmid was digested with NcoI and XhoI and digested with BamHI, and subjected to agarose gel electrophoresis, as shown in FIG. 3B, lane 3 was a single digested fragment, lane 4 was a double digested fragment, and lane 5 was a control plasmid.
Primers were designed using pCas plasmid (conventional commercial product) as a template, and the SpCas9 gene was amplified by PCR using F-2/R-2 (SEQ ID NOS: 9-10), F-3/R-3 (SEQ ID NOS: 11-12) and F-4/R-4 (SEQ ID NOS: 13-14), respectively, to obtain SpCas9-N and SpCas9-C, spCas fragment. The synthesized GB1 and linker (see SEQ ID NO: 25) templates are used, and the designed primers, F-5/R-5 (SEQ ID NO: 15-16) and F-6/R-6 (SEQ ID NO: 17-18) are used for PCR amplification of GB1-N, GB 1-C. The amplified systems are shown in Table 1. The PCR results are shown in FIG. 3, A, B. FIG. 3A, lane 1, spCas9-N, lane 2, spCas9-C, lane 3, GB1-N, lane 4, GB1-C fragment, lane 5, 200bp marker, recovery fragment; in FIG. 3B, the first lane is a SpCas9 fragment, and the second lane is a 200bp marker.
Linearizing the pet28a+ vector with 0.5 mu L, spCas9 1 mu L of the pet28a+ vector and 0.5 mu L, spCas-N/SpCas 9-C1 mu L, GB1-N/GB 1-C0.5 mu L, ddH 2 O3. Mu.L of the infusion enzyme was added to each of the PCR tubes at 50℃for 1 hour. And carrying out heat shock transformation according to the method, screening transformants, and verifying by sequencing to obtain correct pet28a+ -6×his-SpCas9, pet28a+ -10×His-GB1-SpCas9 and pet28a+ -SpCas9-GB1-10×His plasmids. The complete SpCas9-GB1-10 XHis sequence is shown in SEQ ID NO:19.
construction of pet28a+ -SpCas9-GB1-10 XHis triple promoter plasmid
The correctly sequenced pet28a+ multiple promoter plasmid (pet 28a+ -2T7 plasmid) was subjected to double digestion with NcoI and XhoI, and agarose gel electrophoresis was performed after digestion, as shown in FIG. 4, lanes 1 and 3 were digested fragments, and lanes 2 and 4 were control plasmids. The same applies to pet28a+ -3T7 and pet28a+ -4T7 plasmids.
Linearizing the pet28a+ -3T7 vector with fragments 0.5 μ L, spCas 9-C1 μL, GB 1-C0.5 μL, ddH 2 O3. Mu.L of the ligation enzyme (5. Mu.L) was added to the PCR tube, and ligation was performed at 50℃for 1 hour. Heat shock transformation was performed as described previously, the correct transformants were selected, and sequencing verified for the correct plasmid pet28a+ -SpCas9-GB1-10 xhis-3T 7 (i.e., pet28a+ -SpCas9-CGB1-3T 7). The plasmid map of successful construction is shown in FIG. 5.
Similarly, the pet28a+ -2T7, pet28a+ -3T7 or pet28a+ -4T7 vector was linearized with 0.5. Mu. L, spCas 9-N1. Mu.L, GB 1-N0.5. Mu.L, ddH 2 O3. Mu.L of the ligation enzyme (5. Mu.L) was added to the PCR tube, and ligation was performed at 50℃for 1 hour. Heat shock transformation is carried out according to the method, correct transformants are screened, and sequencing is carried out to verify correct plasmids pet28a+ -10 xHis-GB 1-SpCas9-2T7, pet28a+ -10 xHis-GB 1-SpCas9-3T7 and pet28a+ -10 xHis-GB 1-SpCas9-4T7.
Example 2 expression of fusion protein SpCas9-GB1
1. Induction expression of fusion protein SpCas9-GB1
Transferring the identified correct pet28a+ -SpCas9-GB1-10 xHis-3T 7 plasmid into an E.coli expression host E.coli Rosetta (DE 3) to obtain a single colony with stable transformation; inoculating single colonies to a strain containing 100. Mu.g/mL Kan + CHL (CHL) + Culturing overnight at 220rpm and 37 ℃ in LB liquid medium of (chloramphenicol) to obtain overnight bacteria. Overnight bacteria were inoculated into 500mL of LB medium at an inoculation ratio of 1:100, cultured at 200rpm,37℃to OD 600 Reaching 0.6-0.8, adding IPTG (isopropyl thiogalactoside) with the final concentration of 0.5mM, and then culturing for 18-22 hours at the temperature of 16-18 ℃. After the culture, the cells were collected by centrifugation at 8000rpm for 5 minutes at 4 ℃. Then using 30mL TE Buffer to re-suspend the bacteria, and centrifuging at 8000rpm for 5 minutes at 4 ℃ to obtain the fusion expression protein SpCas9-GB1 containing nuclease Cas9-10 xhis cells.
Comparison of the expression level of SpCas9 protein and fusion protein GB1-SpCas9, spCas9-GB1
Plasmids of pet28a-6 XHis-SpCas 9, pet28a+ -SpCas9-GB1-10 XHis-1T 7 (i.e., pet28a+ -SpCas9-GB1-10 XHis), pet28a+ -10 XHis-GB 1-SpCas9-1T7 (i.e., pet28a+ -10 XHis-GB 1-SpCas 9) were induced to be expressed. Respectively centrifuging 2mL of bacterial liquid to obtain thalli, washing twice by using TE Buffer, and obtaining the thalli according to the final OD 600 Adding PBS buffer solution into the solution at the ratio of 10OD/1mL PBS for resuspension, then using ultrasonic disruption, taking 40 mu L of whole bacteria sample, centrifuging the rest liquid at 4 ℃ and 10000rpm, taking 40 mu L of supernatant, removing the supernatant, and then using PBS for resuspension precipitation, thus preparing a precipitation sample. SDS-PAGE running analysis was performed and the results are shown in FIG. 6. Gray scale comparison is performed by using Image J, the expression quantity of the SpCas9-GB1 protein is highest and is 1.68 times of that of the SpCas9 protein without the GB1 fusion. SpCas9-GB1 was subsequently selected for further optimization.
3. Effect of multiple promoters on expression level
The E.coli Rosetta (DE 3) strain transformed by the pet28a+ -10 xHis-GB 1-SpCas9-1T7, 2T7, 3T7 and 4T7 plasmids was induced to be expressed, and the sample was prepared according to the method described above, and the result of SDS-PAGE gel running analysis is shown in FIG. 7A. In the comparison of multiple promoters, the 3, 4-fold T7 promoter has little effect on the expression amount of the target protein, so that the 3-fold T7 promoter is selected later to improve the expression amount.
The plasmids of pet28a+ -SpCas9-GB1-10 xHis-1T 7 and pet28a+ -SpCas9-GB1-10 xHis-3T 7 are induced to be expressed, and the sample preparation and SDS-PAGE running analysis are carried out according to the method. The results are shown in FIG. 7B. The 3-fold T7 promoter obviously improves the expression quantity of the SpCas9-GB1 protein, and the expression quantity of the SpCas9-GB1 driven by the 3-fold T7 promoter is 1.26 times compared by using Image J for gray level analysis.
EXAMPLE 3 purification of fusion protein SpCas9-GB1
Collecting the above induced thallus, mixing with PBS buffer solution, re-suspending, ultrasonic crushing (under the conditions of ultrasonic on for 3s, ultrasonic off for 3s, power of 30%, ultrasonic on ice for 20 min), centrifuging at 4deg.C for 30min at 10000rpm to collect supernatant, and processingFiltering with 0.22 μm filter membrane, directly loading sample, and collecting penetrating fluid; warp Ni 2+ Affinity column purification was performed using Buffer a (500mM NaCl,20mM Tris-HCl, ph=8.0) as the equilibration solution, while phase B (500mM NaCl,500mM Imidazole,20mM Tris-HCl, ph=8.0) was mixed with phase a in a gradient to perform gradient elution (gradient 5%, 10%, 20%, 30%, 50% Buffer B), eluting the target protein, and the protein size was 165KD, and the experimental results are shown in fig. 8.
Ni is added with 2+ The fusion protein SpCas9 solution purified by the affinity chromatography column was subjected to ultrafiltration (500mM NaCl,20mM Tris-HCl,3mM DTT (dithiothreitol), ph=8.0) to remove imidazole and hetero-proteins. Cas9 protein was stored in 50% glycerol after concentration.
Example 4 Activity detection of fusion protein SpCas9-GB1
The sgRNA (Niad-sgRNA) is designed according to the Niad gene (AO 090012001035) locus of Aspergillus oryzae, and the specific sequence is shown in SEQ ID NO:23 from base 21 to 40. Primers were designed, F-7/R-7 (SEQ ID NO: 20-21) was used, and any plasmid containing the fragment of the sgRNA backbone was used as a template to amplify the backbone containing the sgRNA (see SEQ ID NO:23 for specific sequences), followed by agarose gel electrophoresis and fragment recovery. As a result, FIG. 9 shows that lanes 1 and 2 are Niad-sgRNA templates (amplified skeletons containing sgRNA), and lane 5 is DL5000 DNA marker.
In vitro transcription using T7 RNA polymerase and alcohol precipitation extraction using isopropanol were performed as described in Table 2 to give purified Niad-sgRNA.
Table 2: RNA in vitro transcription system
Template DNA | 1μg |
T7 RNA pol/50% glycerol | 2μL |
NTP | 10μL |
RNAase free water | Up to 30μL |
SpCas9-GB1 in vitro cleavage system was configured according to the system of Table 3. A template negative control was set up and Cas9 purchased on the market was set up as a positive control. The system was placed in an incubator at 37℃for 8 hours, and then subjected to agarose gel electrophoresis. The results are shown in FIG. 10, wherein lane 1 is a positive control, lane 2 is a SpCas9-GB1 experimental group, and lanes 3 and 4 are negative controls. The template was sheared in the positive control and experimental groups, indicating that the purified SpCas9-GB1 protein had the correct protein activity and was able to be subjected to gene editing.
Table 3: cas9 protein in-vitro cutting template system
Example 5 application example of fusion protein SpCas9-GB1
The sgRNA (pyrg-sgRNA) was designed according to the Aspergillus niger pyrg gene (An 12g 03570) site, and the specific sequence is shown in SEQ ID NO:24 from base 21 to 40. Primers were designed and F-8/R-7 (SEQ ID NO:22, SEQ ID NO: 21) was used to amplify the backbone containing the sgRNA using any plasmid containing the fragment of the backbone of the sgRNA as template (see SEQ ID NO:24 for specific sequences).
In vitro transcription using T7 RNA polymerase and alcohol precipitation extraction using isopropanol was performed as described in Table 2 to give purified pyrg-sgRNA.
The in vitro assembled RNP complex was transformed into protoplasts of A.niger CBS513.88 (a conventional commercially available product) according to the Aspergillus transformation method of conventional PEG, and observed for the presence of transformants. The results are shown in FIG. 11. The positive plate showed colony growth, the negative plate showed no colony growth, and the transformation plate showed colony growth. Wherein, the positive plate is not added with RNP complex and screening substance (5-fluoroorotic acid and uridine), the negative plate is not added with RNP complex but added with screening substance (5-fluoroorotic acid and uridine), and the conversion plate is added with RNP complex and screening substance (5-fluoroorotic acid and uridine).
Transformants were picked on plates and the genome was extracted in 24 well plates for PCR amplification of the pyrg gene. Sequencing identified a deletion at pyrg at the sgRNA position, as shown in FIG. 12. SpCas9-GB1 can be seen to have the ability to enter the nucleus for gene editing.
The above examples are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above examples, and any other changes, modifications, substitutions, combinations, and simplifications that do not depart from the spirit and principle of the present invention should be made in the equivalent manner, and the embodiments are included in the protection scope of the present invention.
Sequence listing
<110> university of North China
<120> a method for efficiently expressing and purifying Cas9 protein and application thereof
<160> 25
<170> SIPOSequenceListing 1.0
<210> 1
<211> 40
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> F-1
<400> 1
agtgagtcgt attaatttcg ttcggcgtgg gtatggtggc 40
<210> 2
<211> 47
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> R-1
<400> 2
tgtgagcgga taacaattcc ataattttgt ttaactttaa gaaggag 47
<210> 3
<211> 62
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> 2T7-F
<400> 3
taatacgact cactataggt aatacgactc actatagggg aattgtgagc ggataacaat 60
tc 62
<210> 4
<211> 63
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> 2T7-R
<400> 4
cctatagtga gtcgtattac ctatagtgag tcgtattacc tatagtgagt cgtattaatt 60
tcg 63
<210> 5
<211> 81
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> 3T7-F
<400> 5
taatacgact cactataggt aatacgactc actataggta atacgactca ctatagggga 60
attgtgagcg gataacaatt c 81
<210> 6
<211> 82
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> 3T7-R
<400> 6
cctatagtga gtcgtattac ctatagtgag tcgtattacc tatagtgagt cgtattacct 60
atagtgagtc gtattaattt cg 82
<210> 7
<211> 100
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> 4T7-F
<400> 7
taatacgact cactataggt aatacgactc actataggta atacgactca ctataggtaa 60
tacgactcac tataggggaa ttgtgagcgg ataacaattc 100
<210> 8
<211> 101
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> 4T7-R
<400> 8
cctatagtga gtcgtattac ctatagtgag tcgtattacc tatagtgagt cgtattacct 60
atagtgagtc gtattaccta tagtgagtcg tattaatttc g 101
<210> 9
<211> 25
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> F-2
<400> 9
atggataaga aatactcaat aggct 25
<210> 10
<211> 45
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> R-2
<400> 10
cagtggtggt ggtggtggtg ttacaccttc ctcttcttct tgggg 45
<210> 11
<211> 45
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> F-3
<400> 11
ctttaagaag gagatatacc atggataaga aatactcaat aggct 45
<210> 12
<211> 42
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> R-3
<400> 12
ccactgccac ctgctccacc caccttcctc ttcttcttgg gg 42
<210> 13
<211> 45
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> F-4
<400> 13
gtggacagca aatgggtcgc ggaatggata agaaatactc aatag 45
<210> 14
<211> 65
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> R-4
<400> 14
gtcgacggag ctcgaattcg tcacaccttc ctcttcttct tggggtcacc tcctagctga 60
ctcaa 65
<210> 15
<211> 83
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> F-5
<400> 15
aactttaaga aggagatata ccatgggcag cagccatcat catcatcatc accaccacca 60
tcatgccgtg ggcggatccg gtg 83
<210> 16
<211> 39
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> R-5
<400> 16
attgagtatt tcttatccat gctgcctccg ccacccgaa 39
<210> 17
<211> 61
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> F-6
<400> 17
ggtggagcag gtggcagtgg cgcaggggga gccggatata aattgatcct gaacggcaaa 60
a 61
<210> 18
<211> 97
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> R-6
<400> 18
cagtggtggt ggtggtggtg gtgatgatga tgagagcctc ccccaccacc cccggcaccg 60
cttgcccctc cggcttctgt gacagtgaag gttttgg 97
<210> 19
<211> 4395
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> SpCas9-GB1-10×His
<400> 19
atggataaga aatactcaat aggcttagat atcggcacaa atagcgtcgg atgggcggtg 60
atcactgatg aatataaggt tccgtctaaa aagttcaagg ttctgggaaa tacagaccgc 120
cacagtatca aaaaaaatct tataggggct cttttatttg acagtggaga gacagcggaa 180
gcgactcgtc tcaaacggac agctcgtaga aggtatacac gtcggaagaa tcgtatttgt 240
tatctacagg agattttttc aaatgagatg gcgaaagtag atgatagttt ctttcatcga 300
cttgaagagt cttttttggt ggaagaagac aagaagcatg aacgtcatcc tatttttgga 360
aatatagtag atgaagttgc ttatcatgag aaatatccaa ctatctatca tctgcgaaaa 420
aaattggtag attctactga taaagcggat ttgcgcttaa tctatttggc cttagcgcat 480
atgattaaat ttcgtggtca ttttttgatt gagggagatt taaatcctga taatagtgat 540
gtggacaaac tatttatcca gttggtacaa acctacaatc aattatttga agaaaaccct 600
attaacgcaa gtggagtaga tgctaaagcg attctttctg cacgattgag taaatcaaga 660
cgattagaaa atctcattgc tcagctcccc ggtgagaaga aaaatggctt atttgggaat 720
ctcattgctt tgtcattggg tttgacccct aattttaaat caaattttga tttggcagaa 780
gatgctaaat tacagctttc aaaagatact tacgatgatg atttagataa tttattggcg 840
caaattggag atcaatatgc tgatttgttt ttggcagcta agaatttatc agatgctatt 900
ttactttcag atatcctaag agtaaatact gaaataacta aggctcccct atcagcttca 960
atgattaaac gctacgatga acatcatcaa gacttgactc ttttaaaagc tttagttcga 1020
caacaacttc cagaaaagta taaagaaatc ttttttgatc aatcaaaaaa cggatatgca 1080
ggttatattg atgggggagc tagccaagaa gaattttata aatttatcaa accaatttta 1140
gaaaaaatgg atggtactga ggaattattg gtgaaactaa atcgtgaaga tttgctgcgc 1200
aagcaacgga cctttgacaa cggctctatt ccccatcaaa ttcacttggg tgagctgcat 1260
gctattttga gaagacaaga agacttttat ccatttttaa aagacaatcg tgagaagatt 1320
gaaaaaatct tgacttttcg aattccttat tatgttggtc cattggcgcg tggcaatagt 1380
cgttttgcat ggatgactcg gaagtctgaa gaaacaatta ccccatggaa ttttgaagaa 1440
gttgtcgata aaggtgcttc agctcaatca tttattgaac gcatgacaaa ctttgataaa 1500
aatcttccaa atgaaaaagt actaccaaaa catagtttgc tttatgagta ttttacggtt 1560
tataacgaat tgacaaaggt caaatatgtt actgaaggaa tgcgaaaacc agcatttctt 1620
tcaggtgaac agaagaaagc cattgttgat ttactcttca aaacaaatcg aaaagtaacc 1680
gttaagcaat taaaagaaga ttatttcaaa aaaatagaat gttttgatag tgttgaaatt 1740
tcaggagttg aagatagatt taatgcttca ttaggtacct accatgattt gctaaaaatt 1800
attaaagata aagatttttt ggataatgaa gaaaatgaag atatcttaga ggatattgtt 1860
ttaacattga ccttatttga agatagggag atgattgagg aaagacttaa aacatatgct 1920
cacctctttg atgataaggt gatgaaacag cttaaacgtc gccgttatac tggttgggga 1980
cgtttgtctc gaaaattgat taatggtatt agggataagc aatctggcaa aacaatatta 2040
gattttttga aatcagatgg ttttgccaat cgcaatttta tgcagctgat ccatgatgat 2100
agtttgacat ttaaagaaga cattcaaaaa gcacaagtgt ctggacaagg cgatagttta 2160
catgaacata ttgcaaattt agctggtagc cctgctatta aaaaaggtat tttacagact 2220
gtaaaagttg ttgatgaatt ggtcaaagta atggggcggc ataagccaga aaatatcgtt 2280
attgaaatgg cacgtgaaaa tcagacaact caaaagggcc agaaaaattc gcgagagcgt 2340
atgaaacgaa tcgaagaagg tatcaaagaa ttaggaagtc agattcttaa agagcatcct 2400
gttgaaaata ctcaattgca aaatgaaaag ctctatctct attatctcca aaatggaaga 2460
gacatgtatg tggaccaaga attagatatt aatcgtttaa gtgattatga tgtcgatcac 2520
attgttccac aaagtttcct taaagacgat tcaatagaca ataaggtctt aacgcgttct 2580
gataaaaatc gtggtaaatc ggataacgtt ccaagtgaag aagtagtcaa aaagatgaaa 2640
aactattgga gacaacttct aaacgccaag ttaatcactc aacgtaagtt tgataattta 2700
acgaaagctg aacgtggagg tttgagtgaa cttgataaag ctggttttat caaacgccaa 2760
ttggttgaaa ctcgccaaat cactaagcat gtggcacaaa ttttggatag tcgcatgaat 2820
actaaatacg atgaaaatga taaacttatt cgagaggtta aagtgattac cttaaaatct 2880
aaattagttt ctgacttccg aaaagatttc caattctata aagtacgtga gattaacaat 2940
taccatcatg cccatgatgc gtatctaaat gccgtcgttg gaactgcttt gattaagaaa 3000
tatccaaaac ttgaatcgga gtttgtctat ggtgattata aagtttatga tgttcgtaaa 3060
atgattgcta agtctgagca agaaataggc aaagcaaccg caaaatattt cttttactct 3120
aatatcatga acttcttcaa aacagaaatt acacttgcaa atggagagat tcgcaaacgc 3180
cctctaatcg aaactaatgg ggaaactgga gaaattgtct gggataaagg gcgagatttt 3240
gccacagtgc gcaaagtatt gtccatgccc caagtcaata ttgtcaagaa aacagaagta 3300
cagacaggcg gattctccaa ggagtcaatt ttaccaaaaa gaaattcgga caagcttatt 3360
gctcgtaaaa aagactggga tccaaaaaaa tatggtggtt ttgatagtcc aacggtagct 3420
tattcagtcc tagtggttgc taaggtggaa aaagggaaat cgaagaagtt aaaatccgtt 3480
aaagagttac tagggatcac aattatggaa agaagttcct ttgaaaaaaa tccgattgac 3540
tttttagaag ctaaaggata taaggaagtt aaaaaagact taatcattaa actacctaaa 3600
tatagtcttt ttgagttaga aaacggtcgt aaacggatgc tggctagtgc cggagaatta 3660
caaaaaggaa atgagctggc tctgccaagc aaatatgtga attttttata tttagctagt 3720
cattatgaaa agttgaaggg tagtccagaa gataacgaac aaaaacaatt gtttgtggag 3780
cagcataagc attatttaga tgagattatt gagcaaatca gtgaattttc taagcgtgtt 3840
attttagcag atgccaattt agataaagtt cttagtgcat ataacaaaca tagagacaaa 3900
ccaatacgtg aacaagcaga aaatattatt catttattta cgttgacgaa tcttggagct 3960
cccgctgctt ttaaatattt tgatacaaca attgatcgta aacgatatac gtctacaaaa 4020
gaagttttag atgccactct tatccatcaa tccatcactg gtctttatga aacacgcatt 4080
gatttgagtc agctaggagg tgaccccaag aagaagagga aggtgggtgg agcaggtggc 4140
agtggcgcag ggggagccgg atataaattg atcctgaacg gcaaaacttt gaagggcgaa 4200
acaacaacag aagctgttga cgctgctacc gctgaaaaag tatttaaaca gtatgcaaac 4260
gacaacggtg ttgatggaga atggacatac gatgacgcaa ccaaaacctt cactgtcaca 4320
gaagccggag gggcaagcgg tgccgggggt ggtgggggag gctctcatca tcatcaccac 4380
caccaccacc accac 4395
<210> 20
<211> 65
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> F-7
<400> 20
taatacgact cactataggg gaacgcgtca aaaaggctgg gttttagagc tagaaatagc 60
aagtt 65
<210> 21
<211> 19
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> R-7
<400> 21
gcaccgactc ggtgccact 19
<210> 22
<211> 65
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> F-8
<400> 22
taatacgact cactataggg ggtcagcagt accagacgcc gttttagagc tagaaatagc 60
aagtt 65
<210> 23
<211> 116
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> scaffold containing niad-sgRNA
<400> 23
taatacgact cactataggg gaacgcgtca aaaaggctgg gttttagagc tagaaatagc 60
aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt ggcaccgagt cggtgc 116
<210> 24
<211> 116
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> pyrg-sgRNA containing backbone
<400> 24
taatacgact cactataggg ggtcagcagt accagacgcc gttttagagc tagaaatagc 60
aagttaaaat aaggctagtc cgttatcaac ttgaaaaagt ggcaccgagt cggtgc 116
<210> 25
<211> 282
<212> DNA
<213> Artificial sequence (Artificial Sequence)
<220>
<223> synthesized GB1 and linker
<400> 25
gccgtgggcg gatccggtgg ttcaggcggt agttataaat tgatcctgaa cggcaaaact 60
ttgaagggcg aaacaacaac agaagctgtt gacgctgcta ccgctgaaaa agtatttaaa 120
cagtatgcaa acgacaacgg tgttgatgga gaatggacat acgatgacgc aaccaaaacc 180
ttcactgtca cagaaggtgg tgggagcgga ggcggtggca gcggtggcgg cggtagtggc 240
ggtggcggtt cgggcggcgg tggttcgggt ggcggaggca gc 282
Claims (9)
1. A method for efficiently expressing and purifying a Cas9 protein, which is characterized by comprising the steps of: the method comprises the following steps:
step 1, constructing a nuclease Cas9 expression vector pet28a+ -SpCas9-GB1-10 xHis-3T 7 driven by multiple promoters; the SpCas9-GB1-10 xHis sequence is shown in SEQ ID NO: 19; 3T7 refers to the 3-fold T7 promoter;
step 2, expression of the cas9 expression vector pep28a+ -SpCas9-GB1-10 xhis-3T 7: transferring the constructed pet28a+ -SpCas9-GB1-3T7 into a hostE.coli Rosetta (DE 3), a recombinant strain is obtained; transferring and activating the recombinant strain, performing induction expression by using IPTG, and centrifugally collecting thalli to obtain thalli expressing the SpCas9-GB1 protein;
step 3, purification of SpCas9-GB1 protein: suspending the strain in the step 2 by using a buffer solution, performing ultrasonic crushing, centrifuging and collecting the supernatant to obtain soluble SpCas9-GB1 protein in positive clones, filtering to remove cell fragments and particles, directly loading the filtered liquid to a Ni+ affinity chromatography column for purification, and collecting eluted protein to obtain SpCas9-GB1 protein solution; and carrying out ultrafiltration concentration on the obtained SpCas9-GB1 protein solution to obtain the SpCas9-GB1 protein.
2. The method according to claim 1, characterized in that: further comprising step 4:
step 4, application of SpCas9-GB1 protein: the SpCas9-GB1 and the sgRNA are assembled and then used for in-vitro cutting of templates and gene editing by transferring into a fungus host, and whether the SpCas9-GB1 is correctly folded or not is determined to have the capability of cutting DNA and performing gene editing by nuclear insertion.
3. The method according to claim 1 or 2, characterized in that:
the recombinant strain in the step 2 is selected in LB liquid medium of Kan+ and CHL+, and cultured at 37+ -1 ℃ and 200-220 rpm for 8-16 h activation; after activation, according to (1-5): 100 transferring ratio, taking activated bacterial liquid in LB liquid culture medium of Kan+ and CHL+, culturing at 37+ -1deg.C and 200-220 rpm to OD 600 When the concentration is 0.6-0.8, IPTG is added to the final concentration of 0.3-0.8 mM for induction expression.
4. The method according to claim 1 or 2, characterized in that:
the conditions for inducing expression in the step 2 are 16-20 ℃ and 200-220 rpm; the fermentation time is 18-22 h.
5. The method according to claim 1 or 2, characterized in that:
the centrifugation condition in the step 2 is 4-8 ℃, and the centrifugation is carried out at 8000-10000 rpm for 5-10 minutes.
6. The method according to claim 1 or 2, characterized in that:
the conditions of ultrasonic disruption in step 3 are: ultrasonic switch 3s, ultrasonic switch 3s, power 30-40%, ultrasonic on ice for 20-30 min.
7. The method according to claim 1 or 2, characterized in that:
the centrifugation condition in the step 3 is 4-8 ℃, and the centrifugation is carried out at 8000-10000 rpm for 30-40 min.
8. The method according to claim 1 or 2, characterized in that:
in the step 3, the SpCas9-GB1 protein is eluted in a gradient way, the imidazole concentration of Buffer A is 0mM, and the imidazole concentration of Buffer B is 500 and mM; gradient 5%, 10%, 20%, 30%, 50% Buffer B;
Buffer A:500 mM NaCl,20 mM Tris-HCl,PH=8.0;
Buffer B:500 mM NaCl,500 mM Imidazole,20 mM Tris-HCl,PH=8.0。
9. use of the method of high-efficiency expression and purification of Cas9 protein according to any one of claims 1 to 8 for high-efficiency expression and purification of Cas9 protein.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210054940.3A CN114410608B (en) | 2022-01-18 | 2022-01-18 | Method for efficiently expressing and purifying Cas9 protein and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210054940.3A CN114410608B (en) | 2022-01-18 | 2022-01-18 | Method for efficiently expressing and purifying Cas9 protein and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114410608A CN114410608A (en) | 2022-04-29 |
CN114410608B true CN114410608B (en) | 2023-08-22 |
Family
ID=81273117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210054940.3A Active CN114410608B (en) | 2022-01-18 | 2022-01-18 | Method for efficiently expressing and purifying Cas9 protein and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114410608B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117801056A (en) * | 2023-06-29 | 2024-04-02 | 北京百普赛斯生物科技股份有限公司 | Method for purifying target protein from solution |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111893105A (en) * | 2020-08-03 | 2020-11-06 | 中国药科大学 | Cas9 protein expression and purification method |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11913044B2 (en) * | 2018-06-14 | 2024-02-27 | President And Fellows Of Harvard College | Evolution of cytidine deaminases |
-
2022
- 2022-01-18 CN CN202210054940.3A patent/CN114410608B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111893105A (en) * | 2020-08-03 | 2020-11-06 | 中国药科大学 | Cas9 protein expression and purification method |
Non-Patent Citations (1)
Title |
---|
Bacterial Genome Editing Strategy for Control of Transcription and Protein Stability;Lauritsen I等;《Methods Mol Biol.》;第27-37页 * |
Also Published As
Publication number | Publication date |
---|---|
CN114410608A (en) | 2022-04-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10954498B2 (en) | Modified cascade ribonucleoproteins and uses thereof | |
KR102647766B1 (en) | Class II, type V CRISPR systems | |
CN106834323A (en) | Gene editing method based on streptomyces virginiae IBL14 gene cas7-5-3 | |
CN116515797A (en) | Enzymes with RUVC domains | |
CN114410608B (en) | Method for efficiently expressing and purifying Cas9 protein and application thereof | |
US20240301374A1 (en) | Systems and methods for transposing cargo nucleotide sequences | |
JP2024533038A (en) | Systems and methods for translocating cargo nucleotide sequences | |
WO2023028348A1 (en) | Enzymes with ruvc domains | |
CN118019843A (en) | Class II V-type CRISPR system | |
CN114230644A (en) | GP32 protein mutant, recombinant vector, and construction method and application thereof | |
US20210187102A1 (en) | Method of obtaining a polyepitopic protein and polyepitopic dna vector | |
WO2017215174A1 (en) | Marine bacterial gene lfliz and use | |
CN108103044B (en) | Esterase WDEst17, and coding gene and application thereof | |
CN116396949A (en) | Fusion protein with double PET hydrolase activity and method for degrading PET | |
US20240360477A1 (en) | Systems and methods for transposing cargo nucleotide sequences | |
CN117658341A (en) | Application of nitroreductase Ntr3 in degradation of CL-20 | |
Samoilova et al. | Binding of DNA with Abf2p increases efficiency of DNA uptake by isolated mitochondria | |
CN102007218A (en) | A method and kit for purification of recombinant proteins using a self-cleaving ptotein intein | |
CN116284275A (en) | Intein Ssp tau, coding gene and application thereof in preparation of tetrapeptide-5 | |
US20220002353A1 (en) | Dextran affinity tag and use thereof | |
CN116286787A (en) | Nucleic acid enrichment, separation and purification method based on CRISPR-Cas system | |
CN115838745A (en) | Linear DNA template and system suitable for cell-free synthesis of restriction endonuclease BsaI and application thereof | |
CN113046345A (en) | Novel reagent and method for extracting plasmid DNA | |
GB2617659A (en) | Enzymes with RUVC domains | |
CN117402853A (en) | Cas12m protein with DNA (deoxyribonucleic acid) cutting activity and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |